- Home
- IMRN vs AMS Comparison
IMRN vs AMS Comparison
Compare IMRN & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- AMS
- Stock Information
- Founded
- IMRN 1994
- AMS 1980
- Country
- IMRN Australia
- AMS United States
- Employees
- IMRN N/A
- AMS N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- AMS Medical Specialities
- Sector
- IMRN Health Care
- AMS Health Care
- Exchange
- IMRN Nasdaq
- AMS Nasdaq
- Market Cap
- IMRN 14.4M
- AMS 14.6M
- IPO Year
- IMRN N/A
- AMS N/A
- Fundamental
- Price
- IMRN $1.58
- AMS $2.17
- Analyst Decision
- IMRN
- AMS
- Analyst Count
- IMRN 0
- AMS 0
- Target Price
- IMRN N/A
- AMS N/A
- AVG Volume (30 Days)
- IMRN 384.6K
- AMS 16.2K
- Earning Date
- IMRN 08-29-2025
- AMS 11-13-2025
- Dividend Yield
- IMRN N/A
- AMS N/A
- EPS Growth
- IMRN N/A
- AMS N/A
- EPS
- IMRN N/A
- AMS N/A
- Revenue
- IMRN $4,777,422.00
- AMS $29,423,000.00
- Revenue This Year
- IMRN N/A
- AMS $5.06
- Revenue Next Year
- IMRN N/A
- AMS N/A
- P/E Ratio
- IMRN N/A
- AMS N/A
- Revenue Growth
- IMRN 48.63
- AMS 17.84
- 52 Week Low
- IMRN $1.42
- AMS $2.01
- 52 Week High
- IMRN $2.48
- AMS $3.59
- Technical
- Relative Strength Index (RSI)
- IMRN 33.02
- AMS 42.75
- Support Level
- IMRN $1.54
- AMS $2.02
- Resistance Level
- IMRN $1.62
- AMS $2.31
- Average True Range (ATR)
- IMRN 0.13
- AMS 0.10
- MACD
- IMRN -0.03
- AMS 0.01
- Stochastic Oscillator
- IMRN 18.84
- AMS 34.48
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.